KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBT Margin (2016 - 2025)

Pacira BioSciences has reported EBT Margin over the past 16 years, most recently at 0.29% for Q4 2025.

  • Quarterly results put EBT Margin at 0.29% for Q4 2025, down 1334.0% from a year ago — trailing twelve months through Dec 2025 was 2.32% (up 1133.0% YoY), and the annual figure for FY2025 was 2.32%, up 1133.0%.
  • EBT Margin for Q4 2025 was 0.29% at Pacira BioSciences, down from 5.31% in the prior quarter.
  • Over the last five years, EBT Margin for PCRX hit a ceiling of 22.34% in Q2 2023 and a floor of 82.37% in Q3 2024.
  • Median EBT Margin over the past 5 years was 6.73% (2024), compared with a mean of 3.57%.
  • Biggest five-year swings in EBT Margin: crashed -9250bps in 2024 and later skyrocketed 8768bps in 2025.
  • Pacira BioSciences' EBT Margin stood at 3.89% in 2021, then soared by 194bps to 3.67% in 2022, then skyrocketed by 407bps to 18.6% in 2023, then fell by -27bps to 13.63% in 2024, then tumbled by -98bps to 0.29% in 2025.
  • The last three reported values for EBT Margin were 0.29% (Q4 2025), 5.31% (Q3 2025), and 1.06% (Q2 2025) per Business Quant data.